[
  {
    "question": "Female came with decreased sensation to pinprick in bilateral upper limbs?",
    "option_a": "Syringomyelia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Syringomyelia is a disorder characterized by the evolution of a fluid\u2010filled cavity (syrinx) within the spinal cord. This condition typically presents with a bilateral loss of pain and temperature sensation in the upper extremities (often in a 'cape\u2010like' distribution) due to the involvement of the central decussating fibers of the spinothalamic tract. The formation of a syrinx in the central spinal cord (most often in the cervical region) disrupts the crossing fibers of the spinothalamic tract that carry pain and temperature sensations. This central cavitation initially spares the dorsal column functions but can later extend to involve anterior horn cells, leading to weakness. Etiologies include congenital anomalies (e.g., Chiari I malformation), post-traumatic changes, tumors, or inflammatory processes. Patients with syringomyelia typically present with a bilateral loss of pain and temperature sensation in the upper limbs. The classic 'cape distribution' pattern is due to the involvement of fibers that decussate near the central canal. Over time, patients may also exhibit muscle weakness or atrophy if the anterior horns are affected. The diagnosis is primarily confirmed by MRI of the spinal cord. Differential diagnoses include central cord syndrome (often post-traumatic) and anterior cord syndrome. The \u2018cape distribution\u2019 sensory loss is particularly indicative of a centrally-located lesion such as a syrinx. Management depends on symptom severity. Asymptomatic or minimally symptomatic cases may be managed conservatively with observation, while progressive symptoms often warrant neurosurgical interventions such as decompression surgery or shunting. In pregnant patients, MRI without contrast is generally considered safe, and any surgical intervention requires multidisciplinary planning to minimize fetal risk. Option A, Syringomyelia, is correct because the bilateral loss of pain (pinprick sensation) in the upper limbs\u2014the classic 'cape distribution' pattern\u2014is pathognomonic for a syrinx in the cervical spinal cord. 1. A 'cape distribution' of sensory loss strongly suggests a central cord lesion such as syringomyelia. 2. Look for associated signs of Chiari malformation in these patients. Recent studies stress the importance of early diagnosis using high\u2010resolution MRI, and there is growing evidence that timely neurosurgical intervention in progressive cases can halt or reverse neurological deterioration. Advances in minimally invasive techniques continue to improve patient outcomes.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Young female came with symptoms of bilateral lower limb weakness, loss of all sensory modalities up to the umbilicus, with bladder involvement where is the lesion?",
    "option_a": "Thoracic",
    "option_b": "Lumbosacral",
    "option_c": "Cervical",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a spinal cord syndrome where bilateral lower limb weakness, loss of all sensory modalities up to a defined dermatomal level (the umbilicus), and bladder involvement point to a discrete lesion in the spinal cord. The umbilicus is typically innervated by the T10 dermatome. Lesions in the thoracic spinal cord can interrupt ascending and descending tracts responsible for motor function, all sensory modalities, and autonomic regulation. The involvement of the corticospinal tracts leads to weakness while disruption of both the dorsal columns and spinothalamic tracts results in loss of diverse sensory modalities. Bladder involvement indicates the disruption of descending autonomic pathways. A young female with bilateral lower limb weakness and sensory loss up to the umbilicus (T10 level) with bladder dysfunction clearly points toward a thoracic spinal cord lesion. Such presentations are often seen in conditions like transverse myelitis, compressive myelopathy, or an infarct affecting that segment. MRI of the spine is the investigation of choice to localize the lesion and determine its cause (such as inflammatory, compressive, or vascular). Differential diagnoses include: anterior spinal artery syndrome (which may spare dorsal column functions), compressive lesions (e.g., epidural abscess or tumor), and demyelinating conditions (such as multiple sclerosis). For inflammatory causes like transverse myelitis, high-dose corticosteroids are the first line of treatment followed by plasmapheresis if needed. For compressive lesions, urgent surgical decompression is indicated. In pregnant patients, corticosteroid use is typically acceptable under close monitoring, and imaging can be performed with MRI without contrast when necessary. Option A (Thoracic) is correct because the sensory level at the umbilicus corresponds to the T10 dermatome, localizing the lesion to the thoracic region. 1. The umbilicus corresponds to the T10 dermatome \u2013 use this as a landmark for spinal cord localization. 2. Bladder involvement in spinal cord lesions is an indicator of autonomic pathway disruption. Current guidelines advocate early imaging with MRI and prompt initiation of high-dose corticosteroids in inflammatory myelopathies. Recent therapeutic trials in transverse myelitis focus on immunomodulatory treatments to improve recovery.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Localization of laryngeal spasms?",
    "option_a": "Insula",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Laryngeal spasms refer to the sudden, involuntary contraction of the laryngeal muscles leading to vocal cord closure. In the context of neurological disorders, certain cortical regions when involved, especially during focal seizures, can precipitate such spasms. The insular cortex is integral in processing autonomic functions and visceral sensations. Seizures originating from or propagating to the insula can trigger abnormal autonomic responses, including laryngeal spasm. Electrical stimulation studies and intracranial recordings have implicated the insula in generating these phenomena. Patients with insular epilepsy may present with diverse autonomic symptoms such as laryngeal spasm, which can sometimes lead to airway compromise. Recognizing this association is crucial in the workup of patients with atypical seizure manifestations. The diagnostic workup includes EEG and high-resolution MRI. Intracranial EEG may be required to precisely map seizure foci in refractory cases. Differentials include seizures originating from the frontal operculum and other autonomic centers, but the insula remains a key structure given its complex role in visceral sensation. Initial management involves the use of antiepileptic drugs (AEDs) such as levetiracetam or lamotrigine. In refractory cases, surgical evaluation may be considered. In pregnant patients and those who are lactating, AED selection must prioritize fetal safety, with lamotrigine and levetiracetam generally favored for their better safety profiles. Option A (Insula) is correct because multiple reports and electrophysiological studies have demonstrated that seizures originating in the insular cortex can present with laryngeal spasms. 1. Insular epilepsy may present with unusual autonomic symptoms, including laryngeal spasm. 2. Always consider intracranial EEG for accurate localization when noninvasive studies are inconclusive. Recent advances in neuroimaging and electrophysiological monitoring have improved our understanding of the insula\u2019s role in autonomic control and its involvement in epilepsy. Updated guidelines reinforce a tailored AED regimen and, for refractory cases, surgical intervention based on precise seizure localization.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Agent can cause sensory ataxia, vibration, and proprioception loss:",
    "option_a": "Pyridoxine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The question asks about an agent that causes sensory ataxia with loss of vibration and proprioception. These symptoms typically suggest involvement of the dorsal columns of the spinal cord or peripheral large-fiber neuropathy. Pyridoxine (vitamin B6) in toxicity is a well-known cause of predominantly sensory neuropathy. Excessive intake of pyridoxine can lead to neurotoxicity, resulting in axonal degeneration of large-diameter sensory neurons. This degeneration affects proprioceptive fibers and those mediating vibration sense, leading to sensory ataxia. The mechanism is thought to be a direct toxic effect on neuronal membranes and mitochondrial function. Patients with pyridoxine toxicity may present with symptoms such as unsteady gait (sensory ataxia), diminished vibration, and proprioception loss. This clinical picture mimics other posterior column disorders, making a detailed history of vitamin supplementation crucial. The diagnosis is primarily clinical and supported by a history of high-dose vitamin B6 intake. Differential diagnoses include vitamin B12 deficiency (which also leads to dorsal column dysfunction), nitrous oxide abuse, and other toxic neuropathies. Electrophysiological studies (nerve conduction studies) and serum vitamin levels may help in confirming the diagnosis. The primary management strategy is the cessation of high-dose pyridoxine. Symptomatic treatment and supportive care are provided while monitoring for improvement. In pregnancy and lactation, while vitamin B6 is essential and used in low doses (e.g., for nausea management), high-dose supplementation should be avoided due to the risk of neurotoxicity. Option A (Pyridoxine) is correct because excessive pyridoxine is a recognized cause of sensory neuropathy producing sensory ataxia with loss of vibration and proprioception. Other agents might affect the nervous system differently, but high-dose B6 specifically targets large sensory fibers. 1. High doses of vitamin B6 can lead to a reversible sensory neuropathy. 2. Always obtain a detailed supplement history in patients presenting with sensory deficits. Recent studies have delineated safe upper limits for vitamin B6 supplementation and have provided greater insight into the mechanisms of pyridoxine-induced neurotoxicity. Current guidelines emphasize monitoring vitamin intake, particularly in individuals self-medicating with over-the-counter supplements.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Same scenario?",
    "option_a": "MRI of plexus",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question appears to involve the evaluation of a suspected brachial plexus pathology. In cases where a patient\u2019s clinical scenario suggests involvement of nerves in the brachial plexus, MRI of the plexus is the imaging modality of choice due to its excellent soft\u2010tissue resolution and ability to visualize neural structures. Brachial plexus abnormalities may be due to traumatic injury, inflammation, neoplastic infiltration, or post\u2010surgical changes. MRI can detect nerve thickening, edema, or focal lesions; help to differentiate between an inflammatory versus compressive or structural etiology; and thus define the underlying mechanism of nerve dysfunction. Patients with plexopathies can present with pain, dysesthesias, and weakness in a distribution that follows the branches of the brachial plexus. The clinical features correlate with the location of the insult and the involvement of specific cords or trunks, making detailed imaging essential for proper localization. Differentials include cervical radiculopathy, peripheral nerve entrapment syndromes, and post-surgical nerve injuries. A careful history and neurological examination coupled with MRI helps differentiate among these diagnoses by visualizing both the plexus and adjacent structures (such as cervical spine and soft tissues). Management begins with accurate diagnosis. First-line treatment involves conservative measures such as physical therapy and pain management. If a compressive lesion or other surgically remediable pathology is identified on MRI, referral to neurosurgery or peripheral nerve surgery is indicated. In pregnancy or lactation, MRI is used safely (preferably without gadolinium contrast unless absolutely necessary) to minimize fetal exposure. Option A, MRI of the plexus, is correct because it is the optimal imaging study to assess brachial plexus integrity and any associated pathology. No other options were provided, so by default, selecting MRI of the plexus is justified given the clinical context. 1. MRI is the gold standard for evaluating brachial plexopathies due to its superior soft tissue contrast. 2. Clinical localization along the plexus distribution is key prior to imaging. 3. In pregnant patients, non-contrast MRI is typically preferred when imaging the neural axis. Recent studies continue to support the use of high-resolution MRI (with newer techniques such as diffusion-weighted imaging) to better characterize brachial plexus lesions. Current guidelines emphasize correlating clinical findings with imaging results to guide management.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of patient had mastectomy came with arm pain and dysesthesia over the fourth and fifth finger, what to do next?",
    "option_a": "MRI of plexus",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario involves a patient who has undergone mastectomy and now presents with arm pain and dysesthesia over the fourth and fifth fingers. Such symptoms in a post-mastectomy patient raise concern for a brachial plexus involvement, particularly of the lower trunk (C8-T1), or damage to neural structures like the intercostobrachial nerve. MRI of the plexus is therefore used as a first-line imaging modality. Post-mastectomy patients are at risk for nerve injury either directly from surgical trauma (as with axillary dissection) or indirectly from subsequent radiation therapy. Injury to the lower trunk of the brachial plexus or to the intercostobrachial nerve can result in pain and sensory disturbances, notably in the ulnar distribution (affecting the fourth and fifth fingers). The dysesthesia over the fourth and fifth fingers suggests involvement of nerve fibers that contribute to the ulnar component. In the context of mastectomy (and potential axillary dissection or radiation therapy), this clinical presentation is highly suggestive of a plexopathy rather than a focal entrapment neuropathy such as isolated ulnar nerve compression at the elbow. Differential diagnoses include isolated ulnar neuropathy (e.g., cubital tunnel syndrome), intercostobrachial neuralgia, or even cervical radiculopathy. MRI of the brachial plexus differentiates these by providing detailed visualization of the entire plexus and adjacent tissues to assess for nerve thickening, edema, or fibrosis. Upon confirmation by MRI, management typically involves a multidisciplinary approach. First-line management includes pain control, physical therapy, and occupational therapy. In cases related to radiation or post-surgical changes, medical management may be supplemented with neuromodulatory agents. For pregnant or lactating patients, non-contrast MRI is advisable with judicious use of any contrast agents, ensuring both maternal and fetal safety. Option A (MRI of the plexus) is correct because it allows for detailed assessment of the brachial plexus to determine if the pain and dysesthesia are due to plexopathy rather than a more isolated nerve lesion. Other diagnostic steps (such as nerve conduction studies) may follow but MRI is the key imaging modality in this scenario. 1. Post-mastectomy patients are susceptible to nerve injuries resulting from axillary surgery and/or radiation. 2. Dysesthesia in the ulnar distribution should raise suspicion for lower trunk brachial plexopathy. 3. MRI of the plexus is the preferred imaging tool in these cases. Recent guidelines have underscored the importance of early imaging in post-mastectomy patients with unexplained arm symptoms. Advances in MRI technology have improved the detection of subtle nerve injuries and are particularly valuable in monitoring the progression or resolution of radiation-induced changes.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of AIDP NCS at day 5 is:",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": ") is correct because at day 5 the NCS often do not show the typical demyelinating features (such as conduction block, temporal dispersion, or prolonged distal latencies) that become evident later in the disease course. The explanation provided reinforces that early electrophysiological studies can be deceptively normal.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Acute Inflammatory Demyelinating Polyneuropathy (AIDP), the most common variant of Guillain\u2013Barr\u00e9 syndrome (GBS), is an immune-mediated disorder affecting peripheral nerves. In its early stages, especially around day 5, the classic electrophysiological demyelinating features may not have fully developed. AIDP involves immune-mediated destruction of myelin sheaths along peripheral nerves resulting in slowed nerve conduction and conduction block. However, the pathological changes and the resultant electrophysiological manifestations can lag behind the clinical onset, meaning that nerve conduction studies (NCS) performed very early in the course (such as day 5) may be normal or only mildly abnormal. Clinically, patients may already be experiencing progressive weakness and areflexia even when electrophysiological studies do not yet show overt demyelination. This temporal disparity underscores the importance of clinical judgment and potential repeat testing if initial NCS is inconclusive. The differential diagnosis for acute weakness with normal or near-normal early NCS includes early-stage AIDP and other neuromuscular disorders such as myopathies. Serial nerve conduction studies along with cerebrospinal fluid analysis (which classically shows albuminocytologic dissociation) aid in confirming the diagnosis. Given the potential for rapid progression, management is usually initiated on clinical grounds with treatments such as intravenous immunoglobulin (IVIG) or plasmapheresis. In pregnant or lactating patients, IVIG is generally considered safe and is the preferred treatment option given its safety profile. The option marked as 'None' (corresponding to option D) is correct because at day 5 the NCS often do not show the typical demyelinating features (such as conduction block, temporal dispersion, or prolonged distal latencies) that become evident later in the disease course. The explanation provided reinforces that early electrophysiological studies can be deceptively normal. 1. A normal early NCS does not rule out AIDP; clinical suspicion should prompt repeat studies. 2. Albuminocytologic dissociation in CSF supports the diagnosis. 3. Early securement of treatment (IVIG or plasmapheresis) is critical, even when NCS findings are normal. Recent research indicates that electrophysiological abnormalities in AIDP may only become apparent after the first week of symptoms. Updated guidelines emphasize the importance of repeat NCS (often 1\u20132 weeks later) and underscore that treatment decisions should be made based on clinical findings rather than relying solely on early electrophysiological data.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Image of NCS of median nerve motor:",
    "option_a": "Conduction block",
    "option_b": "Temporal dispersion",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This question involves the interpretation of a nerve conduction study (NCS) image of the median nerve motor. Understanding the distinguishing features between conduction block and temporal dispersion is crucial. Temporal dispersion refers to the spreading out (prolongation) of the compound muscle action potential (CMAP) waveforms due to asynchronous conduction among nerve fibers. In demyelinating neuropathies, damage to the myelin sheath results in variable conduction velocities among the individual nerve fibers. This loss of uniform conduction causes the CMAP to become prolonged and dispersed, rather than appearing as a sharply defined waveform. In contrast, conduction block would show a marked reduction in amplitude without necessarily changing the waveform\u2019s shape drastically. Temporal dispersion is often observed in demyelinating conditions such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and in some cases of demyelinating features in carpal tunnel syndrome. Recognizing these findings on NCS helps in diagnosing and differentiating demyelinating neuropathies from primarily axonal injuries. The main differential considerations on NCS include conduction block versus temporal dispersion. The presence of temporal dispersion (extended duration of the CMAP) helps confirm demyelination, while conduction block would suggest a focal reduction in signal amplitude. Clinical correlation with symptoms and possibly additional imaging or laboratory testing can further clarify the diagnosis. Management is directed at treating the underlying demyelinating process. First-line therapies include corticosteroids, IVIG, or plasmapheresis depending on the specific diagnosis (such as CIDP). In cases of carpal tunnel syndrome, conservative management with splinting or steroid injections is often initiated. For pregnant or lactating patients, IVIG is generally considered safe, and non-invasive management strategies are preferred unless the condition is progressive or severely disabling. Option A (conduction block) is incorrect if the image demonstrates a prolonged and dispersed waveform, which is characteristic of temporal dispersion. Option B (temporal dispersion) is correct because the NCS image exhibits the hallmark features of prolonged CMAP duration with a fanning out of the waveform. The other options are either not provided or do not match the classic description seen in the image. 1. Temporal dispersion is a key electrophysiological marker of demyelination. 2. Differentiating between conduction block and temporal dispersion is essential for accurate diagnosis. 3. Early identification of demyelinating features can guide timely treatment decisions. Recent advances in neurophysiology and imaging have reinforced the utility of detailed NCS analysis in diagnosing demyelinating neuropathies. Updated guidelines emphasize combining electrophysiological data with clinical findings to optimize diagnostic accuracy and guide management, particularly in diverse populations including pregnant and lactating patients.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of CIDP. treatment?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "IVIG,",
    "subspecialty": "Neuromuscular",
    "explanation": "CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) is an autoimmune disorder affecting peripheral nerves, marked by chronic or relapsing-remitting weakness and sensory dysfunction. Its pathogenesis centers around immune-mediated damage to myelin. The condition is mediated by both cellular and humoral immune responses that target and destroy segments of peripheral nerve myelin, leading to conduction block and slowed nerve conduction velocity. Inflammatory infiltrates and cytokines contribute to the demyelination process, with recent studies underscoring the role of T-cell responses and antibody-mediated injury. Clinically, patients develop a gradual onset of symmetric, proximal, and distal weakness, often with sensory deficits and areflexia. The disease course (at least 8 weeks in duration) helps differentiate CIDP from its acute counterpart (AIDP). Electrophysiologic studies reveal demyelinating features, which correlate with clinical impairments. Diagnosis relies on a combination of clinical history, neurological examination, nerve conduction studies (revealing prolonged distal latencies, conduction block, slowed conduction velocity), and cerebrospinal fluid analysis (typically showing elevated protein with few cells). Differential diagnoses include Guillain-Barr\u00e9 syndrome (acute onset), hereditary neuropathies, diabetic neuropathy, and other immune-mediated neuropathies. First-line treatments include immunomodulatory therapies: IVIG, corticosteroids, and plasmapheresis. IVIG is a cornerstone because of its robust evidence base and safety profile, particularly in pregnancy and lactation, where its use is generally favored over corticosteroids due to fewer systemic effects. Corticosteroids remain an option when IVIG is contraindicated, while plasmapheresis is used for severe or refractory cases. Current guidelines recommend early initiation of these therapies to improve long-term outcomes. The analysis confirms that therapies such as IVIG, corticosteroids, and plasmapheresis are effective in addressing the immune-mediated demyelination in CIDP. The marked answer, IVIG, is correct as it is one of the first-line treatments. Incorrect options like supportive care alone or treatments targeting infections (antibiotics/antivirals) fail to address the underlying immune pathology. 1. Early immunotherapy in CIDP can halt progression and improve neurological function. 2. Electrophysiological evidence is critical in confirming the diagnosis. 3. IVIG is often preferred in pregnancy due to its favorable safety profile. Recent guidelines (e.g., from the EFNS/PNS) support the use of IVIG as well as corticosteroids and plasmapheresis in CIDP management. Ongoing research is focused on optimizing dosing regimens and exploring combination strategies, particularly in special populations such as pregnant or lactating women.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of AIDP. Dx:",
    "option_a": ", which embodies the diagnosis of AIDP based on the clinical picture of rapid progression, symmetrical weakness, areflexia, and characteristic CSF and electrophysiological findings, is correct. Alternative options suggesting axonal variants, chronic neuropathies, or non",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "AIDP (Acute Inflammatory Demyelinating Polyradiculoneuropathy) is the most common variant of Guillain-Barr\u00e9 syndrome, characterized by rapid onset of weakness and areflexia with an immune-mediated attack on peripheral nerve myelin. Following an antecedent infection, molecular mimicry triggers an autoimmune response against components of peripheral nerve myelin. This immune response leads to segmental demyelination, causing conduction slowing and eventual nerve dysfunction. Patients typically experience quickly progressive, symmetrical muscle weakness beginning in the lower extremities, accompanied by areflexia. CSF studies typically reveal albuminocytologic dissociation (elevated protein with a normal cell count). These features collectively support the diagnosis of AIDP. Diagnosis is based on clinical criteria, supported by nerve conduction studies that reveal features of demyelination (prolonged distal latencies, slowed nerve conduction velocity) and CSF analysis showing elevated protein. Differential diagnoses include axonal variants like AMAN, chronic conditions such as CIDP, and other neuromuscular disorders. First-line management for AIDP includes IVIG or plasmapheresis. IVIG is preferred and considered safe in pregnant and lactating women. Corticosteroids are not effective in AIDP. Supportive care (including respiratory support if needed) is essential to manage complications such as autonomic dysfunction. Option A, which embodies the diagnosis of AIDP based on the clinical picture of rapid progression, symmetrical weakness, areflexia, and characteristic CSF and electrophysiological findings, is correct. Alternative options suggesting axonal variants, chronic neuropathies, or non-demyelinating conditions do not align with the classic presentation of AIDP. 1. Early immunotherapy (IVIG or plasmapheresis) is critical to limit morbidity in AIDP. 2. The presence of albuminocytologic dissociation in CSF is a hallmark finding. 3. Antecedent infections are commonly reported in the patient history. Recent research and updated guidelines from organizations such as the American Academy of Neurology reinforce the efficacy of early IVIG or plasmapheresis in AIDP management. Timely intervention has been shown to significantly improve neurological outcomes.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of CIDP. Dx?",
    "option_a": "",
    "option_b": ") correctly represents the diagnosis of CIDP, as it includes the clinical and electrophysiological criteria (symmetrical involvement, chronic course >8 weeks, demyelination, CSF protein elevation) that are pathognomonic for CIDP. Other options like GBS, hereditary, diabetic, or motor neuron diseases do not match the chronic, immune",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "CIDP is a chronic immune-mediated neuropathy characterized by a progressive or relapsing course, leading to both motor and sensory deficits. Diagnosis hinges on the chronicity of symptoms in addition to typical electrophysiological abnormalities. In CIDP, persistent immune-mediated inflammation leads to segmental demyelination of peripheral nerves. The immune attack involves both cellular and humoral mechanisms, resulting in conduction slowing and block. This process differentiates it from acute inflammatory neuropathies like AIDP. Patients generally present with slowly progressing or relapsing-remitting weakness and numbness of both proximal and distal muscles over a period exceeding 8 weeks. Areflexia, along with electrophysiologic evidence of demyelination, supports the diagnosis. The gradual evolution of symptoms distinguishes CIDP from the rapid progression seen in Guillain-Barr\u00e9 syndrome. Diagnosis is confirmed with nerve conduction studies showing demyelinating features such as prolonged distal latencies, conduction slowing/block, and sometimes temporal dispersion. CSF analysis typically shows elevated protein without a significant increase in cell count. Differential considerations include Guillain-Barr\u00e9 syndrome (acute onset), hereditary neuropathies (genetically-mediated without inflammatory markers), diabetic neuropathy, and motor neuron diseases. Treatment involves immunomodulatory strategies. First-line options include corticosteroids, IVIG, and plasmapheresis. In pregnant or lactating patients, IVIG is particularly favored due to its established safety profile. Treatment is tailored based on severity, response, and potential side effects, with escalation to combination therapy for refractory cases. The marked answer (Option B) correctly represents the diagnosis of CIDP, as it includes the clinical and electrophysiological criteria (symmetrical involvement, chronic course >8 weeks, demyelination, CSF protein elevation) that are pathognomonic for CIDP. Other options like GBS, hereditary, diabetic, or motor neuron diseases do not match the chronic, immune-mediated demyelinating profile. 1. A chronic course (>8 weeks) with electrophysiological demyelinating features is key for diagnosing CIDP. 2. Early immunotherapy can prevent irreversible nerve damage. 3. IVIG is often preferred in special populations, such as pregnant patients. Recent updates in consensus criteria (EFNS/PNS) and treatment guidelines highlight the importance of early diagnosis and initiation of immunotherapy. New studies are exploring biomarkers for better diagnosis and tailored immunotherapy approaches in CIDP.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of AIDP what is the first abnormality in NCS/EMG",
    "option_a": "(prolonged distal motor latency) is correct because it is the most sensitive and earliest electrophysiological finding in AIDP. Other options, such as reduced CMAP amplitude or conduction block, typically occur later in the disease course and are less sensitive as early markers.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "AIDP is an acute demyelinating neuropathy, most commonly seen as the classic form of Guillain-Barr\u00e9 syndrome. It fundamentally affects peripheral nerve conduction due to an immune-mediated attack on the myelin sheath. The autoimmune process in AIDP results in the initial demyelination of distal nerve segments, which is responsible for early changes seen on nerve conduction studies. Prolongation of distal motor latency reflects impaired initiation of nerve impulses due to demyelination. Patients with AIDP typically present with rapid, progressive, and symmetrical weakness, often accompanied by areflexia. The electrophysiological findings mirror the clinical progression, with early changes including prolonged distal motor latency before later developments such as conduction block or temporal dispersion. Diagnosis of AIDP relies on nerve conduction studies that detect demyelinating features. Among these, prolonged distal motor latency is the earliest detectable abnormality. Differential diagnoses include axonal variants of GBS where reduced amplitudes predominate, neuromuscular junction disorders, or other causes of acute weakness. Management of AIDP involves prompt immunotherapy. First-line treatments are IVIG and plasmapheresis, both of which are highly effective when initiated early. In pregnant or lactating women, IVIG is generally preferred for its safety profile. Corticosteroids are not recommended in AIDP. Option A (prolonged distal motor latency) is correct because it is the most sensitive and earliest electrophysiological finding in AIDP. Other options, such as reduced CMAP amplitude or conduction block, typically occur later in the disease course and are less sensitive as early markers. 1. Early NCS in AIDP often reveals prolonged distal motor latency. 2. Timely identification and treatment with IVIG or plasmapheresis are crucial for optimal outcomes. 3. Differentiation between demyelinating and axonal forms is essential for guiding management decisions. Recent studies reconfirm that prolonged distal motor latency is the most sensitive early finding on nerve conduction studies in AIDP. Updated clinical guidelines continue to support early initiation of IVIG or plasmapheresis to reduce morbidity and hasten recovery.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of CIDP. CSF? findings",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "eleva",
    "subspecialty": "Neuromuscular",
    "explanation": "CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) is an immune-mediated disorder affecting the peripheral nerves which causes progressive, relapsing or steadily worsening weakness and sensory deficits. A key diagnostic feature is the phenomenon of albuminocytologic dissociation in the cerebrospinal fluid (CSF): an elevated protein level with a normal cell count. The underlying process in CIDP involves an autoimmune attack against peripheral nerve myelin. This increases the permeability of the blood\u2013nerve barrier, resulting in leakage of protein into the CSF without a corresponding rise in white blood cells. This pattern, termed albuminocytologic dissociation, supports the demyelinating pathology rather than an infectious or inflammatory cell infiltration. Clinically, patients frequently present with symmetric motor weakness (often both proximal and distal) along with sensory disturbances and hyporeflexia. The CSF finding of elevated protein with a normal cell count is a key laboratory feature that correlates with the chronic inflammatory process damaging the nerve roots. The diagnosis is supported by nerve conduction studies that demonstrate slowed conduction velocities and conduction block. Differential diagnoses include Guillain-Barr\u00e9 syndrome (which is acute), multifocal motor neuropathy, and inherited neuropathies. The distinguishing CSF profile (albuminocytologic dissociation) helps differentiate CIDP from infectious or neoplastic conditions, where inflammatory cells would typically be present. First-line therapies include corticosteroids, intravenous immunoglobulin (IVIG), and plasmapheresis. For patients who are pregnant or lactating, IVIG is often preferred due to its favorable safety profile. Second-line immunosuppressants, such as azathioprine, may be considered if first-line options are insufficient. The correct CSF finding in CIDP is an elevated protein level with a normal cell count, which is explained by albuminocytologic dissociation. Options suggesting normal protein or elevations in cell count imply either a lack of blood\u2013nerve barrier disruption or an inflammatory/infectious process, both of which are inconsistent with CIDP. 1) Albuminocytologic dissociation is a hallmark of CIDP. 2) Electrophysiologic studies are essential to confirm the demyelinating pattern. 3) Early differentiation from acute neuropathies like Guillain\u2013Barr\u00e9 syndrome is critical for management. Recent guidelines continue to endorse early immunotherapy, with IVIG, corticosteroids, or plasmapheresis as effective first-line treatments. Advances in neuroimaging and biomarker research are enhancing diagnostic precision in CIDP.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of AIDP. Treatment:",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "IVIG ",
    "subspecialty": "Neuromuscular",
    "explanation": "Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) is the most common form of Guillain\u2013Barr\u00e9 syndrome (GBS). It is characterized by an autoimmune attack on the peripheral nerve myelin triggered by an antecedent infection, leading to a rapid onset of weakness and areflexia. AIDP is thought to be initiated by molecular mimicry, where antibodies generated in response to an infectious agent cross-react with antigens on peripheral nerve myelin. This immune-mediated demyelination leads to slowed nerve conduction and subsequently to the clinical symptoms. Treatments such as IVIG and plasmapheresis work by modulating the immune response and removing pathogenic antibodies. Patients with AIDP typically present with an ascending pattern of paralysis, sensory disturbances, and diminished or absent reflexes. Early intervention is crucial, as respiratory failure can occur if the weakness ascends to the diaphragm. Differential diagnoses include conditions such as myasthenia gravis, botulism, and spinal cord compression. Nerve conduction studies, along with CSF analysis (which may show albuminocytologic dissociation), help to confirm the diagnosis. First-line treatment options are IVIG and plasmapheresis. IVIG is particularly preferred in pregnant or lactating patients due to its safety profile, while plasmapheresis is also effective but requires careful monitoring. Corticosteroids have not proven beneficial in AIDP and are therefore not recommended as monotherapy. IVIG (or plasmapheresis) is the correct treatment option since these therapies directly target the immune-mediated demyelination process. Alternatives like corticosteroids alone or supportive care do not alter the immunopathology, and antibiotics/antivirals are irrelevant unless there is an underlying infection. 1) Early immunomodulatory therapy can significantly improve outcomes in AIDP. 2) Both IVIG and plasmapheresis are equally effective if initiated promptly. 3) Monitoring respiratory function is critical in managing AIDP. Recent randomized controlled trials and updated guidelines from neurology societies reinforce IVIG and plasmapheresis as the standard of care for AIDP. Ongoing research is focused on optimizing treatment timing and dosing to further improve functional outcomes.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of ALS, NCS/ EMG findings?",
    "option_a": "Fasciculations",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder affecting both the upper and lower motor neurons. The diagnosis is primarily clinical and is supported by electrophysiological studies such as EMG, which help identify characteristic patterns of neuronal degeneration. ALS involves the degeneration of motor neurons in the motor cortex, brainstem, and spinal cord. The dying motor neurons exhibit spontaneous electrical discharges, which are manifested on EMG as fasciculations, along with other findings such as fibrillation potentials and positive sharp waves. Clinically, ALS presents with muscle weakness, atrophy, and a mix of upper and lower motor neuron signs. Fasciculations are a common feature during both the clinical examination and on EMG, reflecting lower motor neuron involvement, although they are not exclusive to ALS. Diagnosis is based on clinical evaluation supported by nerve conduction studies (which are usually normal with respect to sensory nerves) and EMG studies. The differential diagnosis includes multifocal motor neuropathy and benign fasciculation syndrome. However, the presence of widespread denervation and reinnervation changes, notably including fasciculations, supports the diagnosis of ALS. Management of ALS focuses on slowing disease progression with medications such as riluzole and edaravone, and supportive care including physical therapy, respiratory monitoring, and nutritional support. In pregnant or lactating patients, the use of riluzole requires careful risk\u2013benefit analysis and counseling due to limited data in these populations. Option A (Fasciculations) is a correct and frequently noted EMG finding in ALS. Although a comprehensive EMG report in ALS would also reveal fibrillation potentials, positive sharp waves, and evidence of reinnervation, the presence of fasciculations remains a high-yield and characteristic finding. 1) Both upper and lower motor neuron signs are needed to confirm an ALS diagnosis. 2) Fasciculations, while not exclusive to ALS, are an important electrophysiological marker when occurring with other denervation features. 3) Electromyography is critical in differentiating ALS from other movement or neuropathic disorders. Recent studies continue to explore the underlying genetic and molecular mechanisms in ALS, and updated treatment guidelines stress the modest benefits of current pharmacotherapy. Research into novel neuroprotective agents remains ongoing.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of AIDP. CSF? Findings",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "album",
    "subspecialty": "Neuromuscular",
    "explanation": "AIDP (Acute Inflammatory Demyelinating Polyradiculoneuropathy) is the most common form of Guillain\u2013Barr\u00e9 syndrome. It is characterized by an acute onset of symmetrical weakness and sensory changes due to immune-mediated damage to peripheral nerve myelin. AIDP occurs when an immune response, typically post-infectious, mistakenly targets peripheral myelin. The disruption of the nerve root's blood\u2013nerve barrier results in leakage of protein into the CSF without a concomitant rise in cell count, a pattern known as albuminocytologic dissociation. Patients often present with rapidly progressive ascending paralysis, areflexia, and potential respiratory involvement. The characteristic CSF finding supports the diagnosis, especially once the protein elevation becomes evident a week or so after symptom onset. Differential diagnoses include infectious or neoplastic conditions (which would typically have an elevated white cell count or low glucose in the CSF) as well as other causes of acute neuropathy. Electrophysiological studies further help in confirming the demyelinating nature of the neuropathy. First-line treatments include IVIG and plasmapheresis. In pregnant or lactating patients, IVIG is generally considered the safer option given its minimal adverse effects on the fetus and neonate. Corticosteroids are not recommended for AIDP based on current evidence. The CSF finding of albuminocytologic dissociation (elevated protein with normal cell count) is pathognomonic in AIDP. Other options, such as a CSF profile with pleocytosis or low glucose, are indicative of infectious or neoplastic etiologies, making them incorrect in this context. 1) Albuminocytologic dissociation is a key diagnostic clue in AIDP. 2) CSF protein levels may be normal early in the disease and typically rise after the first week. 3) Early initiation of immunotherapy is crucial for improved outcomes. Current guidelines from neurology societies continue to endorse IVIG and plasmapheresis as the standard treatment for AIDP. Emerging research is focused on early biomarkers and optimizing treatment protocols to reduce morbidity.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has muscle stiffness, if he did exercise will worsen the symptoms.",
    "option_a": "Paramyotonia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Paramyotonia congenita is a type of non-dystrophic myotonia characterized by muscle stiffness that paradoxically worsens with exercise, particularly in cold environments. Unlike myotonia congenita (which typically exhibits a warm\u2010up phenomenon), paramyotonia demonstrates worsening stiffness with repeated activity. The condition is most often linked to mutations in the SCN4A gene, which encodes the skeletal muscle sodium channel. The mutation leads to abnormal channel inactivation, resulting in delayed repolarization and sustained muscle fiber excitability. Cold temperatures can exacerbate the impaired channel kinetics, intensifying the myotonic stiffness. Patients typically present with episodic muscle stiffness triggered by exercise or exposure to cold temperatures. The worsening with activity is a key clinical clue. Physical examination and history taking reveal these distinctive features, allowing clinicians to differentiate it from other myotonic disorders. Electromyography (EMG) is the diagnostic tool of choice and will show myotonic discharges. Genetic testing for the SCN4A mutation can confirm the diagnosis. Differential diagnoses include myotonia congenita (which shows improvement with exercise) and other channelopathies. A detailed clinical history with trigger identification is essential. Management is conservative and focuses on avoiding triggers such as cold and strenuous exercise. First-line treatment options include sodium channel blockers like mexiletine, which have been shown to reduce myotonia. In pregnant or lactating patients, trigger avoidance remains crucial, and the use of anti\u2010myotonic medications should be carefully considered in consultation with obstetrics; mexiletine should be used only if the benefits outweigh any potential risks. Physical therapy and lifestyle modifications also play supportive roles. Option A (Paramyotonia) is correct because the scenario describes muscle stiffness that worsens with exercise, a hallmark of paramyotonia congenita. Other potential options (if provided) might include disorders such as myotonia congenita, which typically demonstrates improvement with exercise (the \u2018warm-up\u2019 phenomenon), and thus would be inconsistent with the clinical picture described. 1. Paramyotonia congenita worsens with exercise and cold exposure, contrasting with the warm\u2010up phenomenon in myotonia congenita. 2. It is linked to SCN4A mutations affecting the sodium channels. 3. EMG studies reveal characteristic myotonic discharges. Recent studies continue to support the role of sodium channel mutations in the pathogenesis of paramyotonia congenita. Current guidelines advocate for symptomatic treatment with agents such as mexiletine, and ongoing research is focused on better understanding ion channel dysfunction and optimizing therapeutic approaches.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of monomelic amyotrophy?",
    "option_a": "dvocating for conservative management with a cervical collar. Other options such as immunosuppressive therapy, treatment for generalized ALS, or therapies directed at peripheral neuropathy are inappropriate since the pathogenesis of monomelic amyotrophy is not immune",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Monomelic amyotrophy, also known as Hirayama disease, is a benign, focal motor neuron disorder that typically affects a single upper limb. It is most commonly seen in young males and is characterized by slowly progressive muscle atrophy and weakness without sensory deficits. The pathology is thought to involve dynamic anterior displacement of the posterior dura during neck flexion, leading to chronic microtrauma and ischemia of the anterior horn cells in the lower cervical cord. This leads to focal motor neuron degeneration and the observed clinical weakness. Clinically, patients present with an insidious onset of unilateral upper limb weakness and atrophy. The absence of sensory symptoms with the focal, unilateral nature of the weakness distinguishes it from other motor neuron diseases like ALS, which is typically more widespread. Diagnosis is primarily based on clinical history, physical examination, and dynamic magnetic resonance imaging (MRI) of the cervical spine, which may reveal compression during neck flexion. Electromyography (EMG) can also demonstrate denervation limited to the affected limb. Differential diagnoses include cervical spondylotic amyotrophy, early-stage motor neuron disease, and peripheral nerve entrapments. The first-line management is conservative: use of a cervical collar to prevent neck flexion has been shown to halt or slow progression of the disease. Physical therapy and occupational therapy are supportive. Surgical intervention is rarely indicated. In pregnant or breastfeeding patients, conservative measures such as cervical orthosis are safe and remain the treatment of choice. The marked answer (B) is considered correct if it corresponds with the option advocating for conservative management with a cervical collar. Other options such as immunosuppressive therapy, treatment for generalized ALS, or therapies directed at peripheral neuropathy are inappropriate since the pathogenesis of monomelic amyotrophy is not immune-mediated, and the condition is focal and benign. 1. Hirayama disease typically presents in young males with unilateral upper limb weakness and atrophy. 2. Dynamic cervical MRI in neck flexion is key for diagnosis. 3. Early treatment with a cervical collar may prevent progression. Recent studies support the use of cervical collars in early Hirayama disease to avoid neck flexion, with dynamic MRI being valuable for diagnosis. There is growing consensus that early intervention can improve outcomes and reduce long-term disability.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of MMN, Dx?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Multifocal Motor Neuropathy (MMN) is an immune-mediated disorder characterized by asymmetrical, predominantly distal, motor weakness with minimal or no sensory involvement. It is important to differentiate MMN from other motor neuron diseases because it is treatable. The disease is believed to be immune-mediated, with antibodies (often anti-GM1) implicated in the pathogenesis. These antibodies target components of the nerve membrane, particularly affecting the myelin, and lead to the development of conduction blocks along motor nerves. However, the diagnosis is not solely based on antibody presence, as they may be absent in some patients. Patients typically present with slowly progressive, asymmetric weakness without sensory loss. The hallmark finding on nerve conduction studies is the presence of motor conduction block, which distinguishes MMN from other conditions such as amyotrophic lateral sclerosis (ALS) where conduction block is absent. The diagnosis relies on a combination of clinical evaluation and electrophysiological studies. Nerve conduction studies (NCS) showing conduction block in motor nerves are key. Differential diagnoses include ALS (which has widespread involvement and both upper and lower motor neuron signs), chronic inflammatory demyelinating polyneuropathy (CIDP), and other focal neuropathies. Anti-GM1 antibodies, if present, can support the diagnosis but are not definitive. The first-line treatment for MMN is intravenous immunoglobulin (IVIG), which has been shown to improve strength and function. Second-line agents, such as cyclophosphamide or rituximab, may be considered in refractory cases, though evidence is less robust. For pregnant and lactating patients, IVIG is generally considered safe, but treatment decisions should be made in consultation with maternal-fetal specialists. The marked answer (B) is correct if it implies that the diagnosis of MMN is best supported by electrophysiological findings, particularly the demonstration of conduction block on electromyography (EMG). Other options, such as relying solely on anti-GM1 antibodies, sensory nerve conduction studies, elevated CSF protein, or muscle biopsy, do not provide the same level of diagnostic accuracy and are either nonspecific or misleading. 1. MMN should be suspected in patients with asymmetric, purely motor neuropathy and conduction blocks on electrodiagnostic studies. 2. Unlike ALS, MMN does not involve sensory deficits and is treatable. 3. IVIG remains the cornerstone of therapy. Recent guidelines and studies continue to highlight the diagnostic importance of motor conduction block on nerve conduction studies in MMN and support IVIG as effective first-line therapy. Ongoing research is exploring alternative immunomodulatory strategies for cases that are refractory to treatment.",
    "exam_year": "2018",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of FSHD. What is the Dx?",
    "option_a": "is correct if it represents the diagnosis of FSHD because the clinical features\u2014facial weakness, scapular winging, and humeral muscle involvement\u2014are highly suggestive of FSHD. Other options such as Duchenne muscular dystrophy, limb",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Facioscapulohumeral Muscular Dystrophy (FSHD) is a hereditary muscular dystrophy that primarily affects the muscles of the face, shoulder girdle, and upper arms. It typically presents with progressive facial weakness and scapular winging. FSHD is most commonly associated with a contraction of the D4Z4 repeat on chromosome 4q35. This genetic alteration results in the aberrant expression of the DUX4 gene, which is toxic to muscle cells and leads to progressive muscle degeneration. Modifier genes, such as SMCHD1, may also influence disease severity. Patients with FSHD often present during adolescence or early adulthood with slowly progressive asymmetric weakness of facial muscles, shoulder girdle involvement, and eventual scapular winging. The pattern of muscle involvement and the age of onset help distinguish FSHD from other muscular dystrophies. Diagnosis is confirmed by genetic testing that demonstrates D4Z4 repeat contraction on chromosome 4q35. EMG studies may show a myopathic pattern, and muscle biopsy, while not always necessary, can support the diagnosis. Differential diagnoses include Duchenne Muscular Dystrophy (which presents in early childhood with proximal lower limb involvement), limb-girdle muscular dystrophies, myasthenia gravis, and inclusion body myositis. There is currently no cure for FSHD. Management is supportive and multidisciplinary, involving physical therapy, occupational therapy, and the use of assistive devices to maintain mobility and function. Low-impact exercise and aerobic conditioning are recommended. Genetic counseling is a critical component for patients planning families. In pregnant and lactating patients, management remains supportive; exercise and physical therapy can be continued with appropriate modifications based on symptom severity. Option A is correct if it represents the diagnosis of FSHD because the clinical features\u2014facial weakness, scapular winging, and humeral muscle involvement\u2014are highly suggestive of FSHD. Other options such as Duchenne muscular dystrophy, limb-girdle muscular dystrophy, or myasthenia gravis have distinct clinical presentations and do not match the described pattern. 1. FSHD characteristically presents with facial weakness and scapular winging, and it has an autosomal dominant pattern. 2. Genetic testing confirming D4Z4 repeat contraction on chromosome 4q35 is diagnostic. 3. Supportive management, including tailored physical therapy, is the mainstay of treatment. Current research continues to explore the role of DUX4 gene expression in the pathogenesis of FSHD and potential gene-targeted therapies. Despite advances in understanding the disease mechanism, clinical management remains focused on symptomatic and supportive care with a strong emphasis on multidisciplinary approaches and genetic counseling.",
    "exam_year": "2018",
    "exam_type": "Part I"
  }
]